Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation

Shannon Pretzel, Katherine Kuhn, Lubna Pal, Alex Polotsky, Hugh S Taylor, Heping Zhang, Jared Robins, Steven L Young, Nanette Santoro, Shannon Pretzel, Katherine Kuhn, Lubna Pal, Alex Polotsky, Hugh S Taylor, Heping Zhang, Jared Robins, Steven L Young, Nanette Santoro

Abstract

The Pre-IVF Treatment with a GnRH Antagonist in Women with Endometriosis (PREGnant) Trial (clinicaltrials.gov no. NCT04173169) was designed to test the hypothesis that 60-day pre-treatment with an oral GnRH antagonist in women with documented endometriosis and planning an IVF cycle will result in a superior live birth rate to placebo. Eight hundred fourteen women are required from 4 national sites. To determine the feasibility of using an electronic medical record (EMR)-based strategy to recruit 204 participants at the Colorado site, we conducted a survey of women within the UCHealth system. Eligible women, identified using relevant ICD-10 codes, were invited to complete a 6-question survey to assess planned utilization of IVF, potential interest in participation, and whether delays in treatment due to COVID-19 would influence their decision to participate. Of 6354 age-eligible women with an endometriosis diagnosis, 421 had a concurrent infertility diagnosis. After eliminating duplicates, 212 were emailed a survey; 76 (36%) responded, 6 of whom reported no endometriosis diagnosis. Of the remaining 70, 29 (41%) were planning fertility treatment; only 19 planned IVF. All 19 expressed interest in participation. COVID-19 delays in treatment were not considered as a factor affecting participation by 8/19; the remaining 11 felt that it would "somewhat" affect their decision. None reported that they would not consider participation because of COVID-19. EMR-based recruitment for an endometriosis clinical trial is feasible although the overall yield of participants is low. Delays in treatment due to COVID-19 did not appear to overly influence potential recruitment.

Keywords: Endometriosis; GnRH antagonist; In vitro fertilization; Infertility.

Conflict of interest statement

SP, KK, LP, AP, JR, HZ, and NS report no relevant conflicts of interest. SY has served as a consultant to AbbVie. HST has received grant support to his institution from AbbVie.

© 2021. Society for Reproductive Investigation.

Figures

Fig. 1
Fig. 1
Flow diagram of the survey
Fig. 2
Fig. 2
Table of the survey questions

References

    1. Eisenberg VH, et al. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125(1):55–62. doi: 10.1111/1471-0528.14711.
    1. Morassutto C, et al. Incidence and estimated prevalence of endometriosis and adenomyosis in northeast Italy: a data linkage study. PLoS ONE. 2016;11(4):e0154227. doi: 10.1371/journal.pone.0154227.
    1. Kuroda K, et al. The impact of endometriosis, endometrioma and ovarian cystectomy on assisted reproductive technology. Reprod Med Biol. 2009;8(3):113–118. doi: 10.1007/s12522-009-0021-1.
    1. Sanchez AM, et al. The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma-mediated damage to the ovary. Hum Reprod Update. 2014;20(2):217–230. doi: 10.1093/humupd/dmt053.
    1. Shah DK. Diminished ovarian reserve and endometriosis: insult upon injury. Semin Reprod Med. 2013;31(2):144–149. doi: 10.1055/s-0032-1333479.
    1. Lessey BA, Kim JJ. Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why. Fertil Steril. 2017;108(1):19–27. doi: 10.1016/j.fertnstert.2017.05.031.
    1. Surrey ES, et al. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril. 2002;78(4):699–704. doi: 10.1016/S0015-0282(02)03373-3.
    1. Taylor HS, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40. doi: 10.1056/NEJMoa1700089.
    1. Georgiou EX, et al. Long-term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with endometriosis. Cochrane Database Syst Rev. 2019;2019(11).
    1. Younis JS, Ben-Ami M, Ben-Shlomo I. The Bologna criteria for poor ovarian response: a contemporary critical appraisal. J Ovarian Res. 2015;8:76. doi: 10.1186/s13048-015-0204-9.
    1. Practice Committee of the American Society for Reproductive Medicine. Electronic address Aao et al. ASRM standard embryo transfer protocol template: a committee opinion. Fertil Steril. 2017;107(4):897–900. doi: 10.1016/j.fertnstert.2017.02.108.
    1. Harris PA, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Effoe VS, et al. The use of electronic medical records for recruitment in clinical trials: findings from the Lifestyle Intervention for Treatment of Diabetes trial. Trials. 2016;17(1):496. doi: 10.1186/s13063-016-1631-7.
    1. Carugno J, et al. COVID-19 pandemic. Impact on hysteroscopic procedures: a consensus statement from the Global Congress of Hysteroscopy Scientific Committee. J Minim Invasive Gynecol. 2020;27(5):988–992. doi: 10.1016/j.jmig.2020.04.023.
    1. BezerraEspinola MS, et al. Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk. J Reprod Immunol. 2021;144:103271. doi: 10.1016/j.jri.2021.103271.
    1. Sathian B, et al. Impact of COVID-19 on clinical trials and clinical research: a systematic review. Nepal J Epidemiol. 2020;10(3):878–887. doi: 10.3126/nje.v10i3.31622.
    1. Harrison S, et al. Methods to increase response rates to a population-based maternity survey: a comparison of two pilot studies. BMC Med Res Methodol. 2019;19(1):65. doi: 10.1186/s12874-019-0702-3.
    1. Cook DA, et al. Incentive and reminder strategies to improve response rate for internet-based physician surveys: a randomized experiment. J Med Internet Res. 2016;18(9):e244. doi: 10.2196/jmir.6318.
    1. Ozkan S, Murk W, Arici A. Endometriosis and infertility: epidemiology and evidence-based treatments. Ann N Y Acad Sci. 2008;1127:92–100. doi: 10.1196/annals.1434.007.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit